Alkermes plc (ALKS) announced Tuesday positive topline results from ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness), a first-of-its-kind, six-month study evaluating the efficacy, safety and tolerability of ARISTADA (aripiprazole lauroxil) and INVEGA SUSTENNA (paliperidone palmitate) when used to initiate patients experiencing an acute exacerbation of schizophrenia in the hospital and maintain treatment in an outpatient setting.
from RTT - Biotech http://bit.ly/2D29wgo
via IFTTT
No comments:
Post a Comment